Physician profile
Alice Abraham
NPI 1083857213
$5,884.91
in general payments reported to CMS, 2019-2025
49 companies · $825 in 2025
The $825 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $603 · 2021: $806 · 2022: $824 · 2023: $630 · 2024: $837 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,291.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $773.35 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $709.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $505.64 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $484.96 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $435.52 | 2019-2022 | |
| Mannkind Corporation | $247.92 | 2019-2025 | |
| Amgen INC. | $238.10 | 2019-2025 | Evenity, Prolia, Tepezza |
| Amneal Pharmaceuticals LLC | $217.74 | 2020-2025 | Unithroid |
| Merck Sharp & Dohme LLC | $182.92 | 2019-2025 | Keytruda |
| Corcept Therapeutics | $180.77 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $176.48 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.09 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $151.81 | 2020-2022 | |
| Medtronic, INC. | $100.76 | 2021-2023 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $100.32 | 2022-2025 | Strensiq |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.